🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Grateful for the opportunity to work with the incredible Van Morris, MD on this phase I/II trial of encorafenib, cetuximab and nivolumab in pts with BRAF V600E mutated mCRC who progressed on prior treatment with BRAF + EGFR targeted tx. - While the addition of Nivo did not seem to

‼️ Not all EGFR mutations are the same. Dr. Xiuning Le MD PhD takes us through treatment options for EGFR PACC mutations. ▫️PACC mutations ~12% of EGFR mutations, often as compound mutations ▫️Current SOC is heterogenous ▫️Novel TKIs under development #TTLC25 IASLC

Congrats Kelsey Pan, MD, MPH on the fantastic oral abstract presentation on a large global cohort of patients with LMD and experience with CNS penetrant TKI. Intrathecal amivantamab trial coming soon ! Xiuning Le MD PhD

Congrats to Kelsey Pan, MD, MPH for her fantastic oral abstract talk #TTLC25 on outcomes in pts w/ LMD from NSCLC. Key finding was improvement in OS w/ CNS-penetrant TKIs in pts w/ NSCLC with oncogenic drivers. Incredibly important multi-institutional study addressing a huge unmet need

#TTLC “Best of Oral Abstracts” from a rising star Kelsey Pan, MD, MPH Biagio Ricciuti, MD PhD IASLC Eric K. Singhi, MD MD Anderson Cancer Center 👉 We assembled the largest international cohort of LMD #lungcancer (592 pts) #LMD #lungcancer. We investigated: (1) What is the LMD overall survival (LM-OS) for

Proud of my amazing first-year continuity clinic fellow, Dr. Parma, for receiving the IASLC #TTLC25 Education Award to present our real-world experience on small cell lung cancer. Bingnan Zhang Lauren Averett Byers, MD Xiuning Le MD PhD MD Anderson Cancer Center

Such a high-yield review of systemic treatments for thymic malignancies by Dr. Mehmet Altan MD Anderson Cancer Center , including exciting emerging therapies: Sacituzumab govitecan Jennifer A. Marks, MD Chul Kim, PRTH-101, and agents targeting MTAP del #TTLC25

Loved this moment- I’m so lucky to have such brilliant, supportive, and inspiring female role models as my current + future mentors in thoracic oncology! Xiuning Le MD PhD Ticiana Batista (Leal) And thankful to IASLC #TTLC25 for connecting me to many more around the nation! 🫁❤️

And just like that, I’m already a lame duck chief. Congrats to our new MD Anderson Cancer Center heme/onc fellowship chiefs for 2025-2026: Jen Marvin-Peek, MD Michael LaPelusa, MD Hannah Goulart Sushanth Gouni Laura Amin, MD Tony Zhuang

HARMONi-2 now published! It will be important to see OS outcomes, confirmation of benefit in Western cohorts, and comparison to pembro/chemo especially for the PD-L1 1-49% subpopulation. Definitely exciting future directions ahead

Always excited to hold lung cancer lectures at our Academic Tuesdays! 😊 Thanks so much Eric K. Singhi, MD for this super helpful review of treatment strategies while incorporating patient-directed education resources!

🦋 MARIPOSA: Amivantamab + Lazertinib prolongs overall survival compared to Osimertinib in EGFR mut. NSCLC - toxicity management remains a challenge & key to implement supportive care & optimize current supportive care recommendations. HR 0.75 (95% CI 0.61-0.92) Median OS: NR

Key points: -no OS benefit with SRS in TKI era -pt w/o b/l ctDNA do not benefit from intensification -brain and/or liver need intensification EGFR Resisters EGFR Positive Lung Cancer UK Xiuning Le MD PhD #TLC25 #TLC2025 #lcam #lcsm TLC Conference IDEOlogy Health

#AACR25 is just around the corner! I’m honored to share our latest research from MD Anderson Cancer Center as oral presentations. Eric K. Singhi, MD 👉 I will present our global cohort of #LMD, a global collaboration with Alfredo Addeo MD Kelsey Pan, MD, MPH Ticiana Batista (Leal) Heather Wakelee and other colleagues.

Thank you OncoDaily! Honored to be on the ballot for the 2025 IASLC Board of Directors and look forward to the opportunity to expand optimal lung cancer care and clinical trials on a global scale. Suresh S. Ramalingam, MD, FASCO IASLC Winship Cancer Institute of Emory University

Zongertinib in #HER2 NSCLC simultaneous publication NEJM with #AACR25 presentation by Dr. John Heymach. In previously treated HER2 TKD mt NSCLC, RR 71%, duration of response 14.1m, mPFS 12.4m. G3 AEs in only 17% - diarrhea in 56% of pts but only 1 single case of G3 or higher.

Grateful for such wonderful colleagues and mentors in the thoracic onc world!